Abstract:
Methods for treating, adhering, or sealing biological tissue are provided. The methods include combining solutions containing a polymer component and a dendrimer component capable of reacting with each other, and at least one of the components includes a substituent capable of photoreversible dimerization that can be reversibly dimerized. Drug delivery compositions and kits containing these two components also are provided.
Abstract:
Theranostic nanoprobes are provided for overcoming cancer multidrug resistance, and methods for treating biological tissue, including cancerous tissue. The theranostic nanoprobes may include gold nanoparticles functionalized with DNA-hairpin. The DNA-hairpin may be configured to hybridize to a complementary target, which may silence or lessen the multidrug resistance of cancer cells. The theranostic nanoprobes may be configured to release a chemotherapeutic agent upon hybridization of the DNA-hairpin to a target molecule.
Abstract:
The present disclosure describes methods of treating a skin disorder in a subject in need thereof and methods of locally suppressing an immune response in a tissue of a subject in need thereof. The methods can include contacting a microneedle array comprising a plurality of microneedles with a skin surface of the subject, wherein the plurality of microneedles comprises: i) a degradable hyaluronic acid polymer comprising a disulfide bond, and ii) a therapeutic agent; and applying pressure on the microneedle array such that the plurality of microneedles penetrates the skin surface, thereby releasing the therapeutic agent beneath the skin surface while simultaneously capturing ISF for successive analysis.
Abstract:
Provided herein are RNA triple helix structures. The RNA triple helix may be associated with a dendrimer to form an RNA triple helix-dendrimer conjugate, which may be applied to a biological tissue, such as a tumor. The RNA triple helix-dendrimer conjugate may be disposed in a hydrogel. The hydrogel may be applied to a biological tissue, such as a tumor. The hydrogel and/or dendrimer may control the release of the RNA triple helix. Methods of treating a biological tissue and kits also are provided.
Abstract:
Biocompatible adhesive materials, such as for use with biological tissues and/or medical implants, are provided, as well as methods and kits for making and using the biocompatible adhesive materials. The biocompatible adhesive materials include a dendrimer component and a polymer component, and may be tailored for specific tissue types and conditions.
Abstract:
A nanoparticle composition including: a first polymer conjugated to a drug by a linker to form a first polymer compound, the first polymer compound having a net negative charge; and a second polymer conjugated to at least one positively charged group to form a second polymer compound, the second polymer compound having a net positive charge, and the first polymer compound and the second polymer compound interacting electrostatically to form a nanoparticle.
Abstract:
A hydrogel particle comprising: cross-linked dextran aldehyde (oxidized dextran), comprising the redox sensitive disulfide cross-linker cystamine (2,2'-disulfanediyldiethanamine), the anti-tumor agent doxorubicin conjugated to the cross-linked polymer by a pH sensitive imine bond and the cell penetrating peptide RGD, for use in chemotherapy.
Abstract:
Abstract of the Disclosure Provided herein are compositions that include a dendrimer to which a drug and a binding peptide are conjugated. The binding peptide may be configured to bind to a receptor that is overexpressed by a diseased cell, such as a cancer cell. The compositions may include a hydrogel in which the dendrimer-drug conjugate is dispersed. Methods of drug delivery and kits also are provided.
Abstract:
Provided herein are methods for treating, adhering, or sealing biological tissue with a material, such as a hydrogel, that may include phyllosilicate nanoplatelets. The phyllosilicate nanoplatelets can have a high aspect ratio, a low aspect ratio, or be a mixture of high aspect ratio and low aspect ratio nanoplatelets. Drug releasing compositions and kits also are provided herein.
Abstract:
The present disclosure describes microneedle array compositions comprising a plurality of microneedles projecting from a substrate. Each microneedle of the plurality of microneedles comprise a penetrating tip and a base that is integrally connected with the substrate, wherein each microneedle of the plurality of microneedles is a porous microneedle composed of a degradable hyaluronic acid polymer comprising a disulfide bond.